Baricitinib remains safe, effective in RA at 8.4 years

Sumary of Baricitinib remains safe, effective in RA at 8.4 years:

• A long-term safety study of baricitinib for rheumatoid arthritis, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to a speaker at ACR Convergence..
• “This [study] added to prior integrated safety analyses of baricitinib by reporting on additional years of exposure,”.
• A long-term safety study of baricitinib for RA, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to Kevin Winthrop, MD, MPH..
• These included one phase 1, three phase 2 and five phase 3 trials — all completed — and one ongoing long-term extension study..
• Meanwhile, major adverse cardiovascular events were assessed in the phase 3 trials and in the long-term extension..
• Incidence rates for serious infections were analyzed by age group through week 24 for patients who received either placebo or 4 mg of baricitinib in seven phase 2 or 3 trials —identified as the “bari-RA-PC analysis set”…

Want to know more click here go to health news source.

From Healio - November 9, 2020May 9, 2021